Comparison of Anemia Outcomes between SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Patients with Chronic Kidney Disease: Multi-institutional Cohort Study with Target Trial Emulation in Taiwan

被引：0
|
作者：
Shao, Shih-Chieh [1 ]
Hu, Jia-Chian [2 ]
Tsai, Daniel Hsiang-Te [3 ]
Chuang, Albert Tzu-Ming [2 ]
Liu, Kuan-Hung [4 ]
Lai, Edward Chia-Cheng [5 ]
机构：
[1] Keelung Chang Gung Mem Hosp, Keelung, Taiwan
[2] Natl Cheng Kung Univ, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Sch Pharm, Coll Med, Tainan, Taiwan
[4] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[5] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med, Tainan, Taiwan
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1193
引用
收藏
页码：537 / 537
页数：1
相关论文
共 50 条
  • [21] Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study
    Narasaki, Yoko
    Kovesdy, Csaba P.
    You, Amy S.
    Sumida, Keiichi
    Mallisetty, Yamini
    Surbhi, Satya
    Thomas, Fridtjof
    Amin, Alpesh N.
    Streja, Elani
    Kalantar-Zadeh, Kamyar
    Rhee, Connie M.
    LANCET REGIONAL HEALTH-AMERICAS, 2024, 36
  • [22] Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
    Prattichizzo, Francesco
    Candia, Paola de
    Ceriello, Antonio
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 120
  • [23] Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
    Edwards, Khary
    Li, Xilong
    Lingvay, Ildiko
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04): : 920 - 930
  • [24] Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
    Yaofu Zhang
    Li Jiang
    Junheng Wang
    Tongxin Wang
    Chieh Chien
    Weijun Huang
    Xiaozhe Fu
    Yonghua Xiao
    Qiang Fu
    Shidong Wang
    Jinxi Zhao
    Cardiovascular Diabetology, 21
  • [25] Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
    Zhang, Yaofu
    Jiang, Li
    Wang, Junheng
    Wang, Tongxin
    Chien, Chieh
    Huang, Weijun
    Fu, Xiaozhe
    Xiao, Yonghua
    Fu, Qiang
    Wang, Shidong
    Zhao, Jinxi
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [26] Influence of Preceding Medications on the Renal Outcomes of Japanese Diabetics Treated with SGLT2 Inhibitors and GLP-1 Receptor Agonists
    Kobayashi, Kazuo
    Toyoda, Masao
    DIABETES, 2023, 72
  • [27] Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation
    Rroji, Merita
    Spahia, Nereida
    Figurek, Andreja
    Spasovski, Goce
    BIOMEDICINES, 2025, 13 (03)
  • [28] CARDIOLOGIST USE OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS SINCE RELEASE OF FAVORABLE CARDIOVASCULAR OUTCOMES TRIALS: A NATIONAL STUDY
    Adhikari, Rishav
    Heyward, James
    Alexander, G. Caleb
    Blaha, Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1468 - 1468
  • [29] Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study
    DeRemer, Christina E.
    Vouri, Scott M.
    Guo, Jingchuan
    Donahoo, William T.
    Winterstein, Almut G.
    Shao, Hui
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (09)
  • [30] Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on risk of diabetic eye complications
    Tsai, Yi-Hsuan
    Hemphill, Nefertiti OjiNjideka
    Kurth, Tobias
    DIABETOLOGIA, 2025, 68 (01) : 247 - 248
12345